Atara Biotherapeutics receives FDA clearance for Phase 1 trial of ATA3219, an allogeneic anti-CD19 CAR T-cell therapy for lupus nephritis.
Atara Biotherapeutics received FDA clearance for its IND application for ATA3219, an allogeneic anti-CD19 CAR T-cell monotherapy for treating systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). The Phase 1 trial aims to evaluate safety and preliminary efficacy. If successful, ATA3219 could become a curative, off-the-shelf cell therapy option for severe autoimmune diseases.
February 29, 2024
4 Articles